Bill Baruch is looking at AbbVie as a healthcare name outside of the tech trade. He pointed to 7 percent earnings growth and an expected 24 percent revenue growth ahead, with Skyrizi and Rinvoq now making up for the revenue AbbVie lost as Humira came off patent. The stock is only up about 7 percent on the year and is trying to break out here. He said he likes healthcare broadly right now, also mentioning Eli Lilly in the same breath. Watch the full discussion here.